Gout Management Guidelines

Introduction to Gout Management

The American College of Rheumatology strongly recommends allopurinol as the first-line urate-lowering therapy (ULT) for gout management, with febuxostat as an alternative option, while colchicine serves a different purpose as an anti-inflammatory agent for flare prophylaxis and treatment 1, 2

Allopurinol is a xanthine oxidase inhibitor that reduces uric acid production, indicated for long-term management of hyperuricemia in gout to prevent flares and reduce tophi 1

The American College of Rheumatology strongly recommends allopurinol as the first-line ULT for all patients, including those with CKD stage ≥3 1, 2

Allopurinol requires dose adjustment in renal impairment, starting at ≤100 mg/day (lower in CKD stage ≥3) 1, 2
Febuxostat may be preferred in patients with CKD, as it does not require dose adjustment in mild to moderate renal impairment 3

Allopurinol should be started at a low dose (≤100 mg/day, lower in CKD) and titrated to achieve target serum urate <6 mg/dL, with a maximum FDA-approved dose of 800 mg/day 1, 2

For long-term management of hyperuricemia in gout, the first-line treatment is allopurinol (start low, titrate to target), with febuxostat as an alternative if allopurinol is ineffective or not tolerated 1, 2
For patients with moderate-to-severe CKD, either allopurinol (adjusted dose) or febuxostat may be used 1, 3

Starting ULT without anti-inflammatory prophylaxis can lead to flares, and colchicine or other prophylaxis should always be initiated when starting allopurinol or febuxostat 1, 2
Inadequate allopurinol dosing can occur if doses >300 mg/day are not used to achieve target serum urate 1, 2
Stopping ULT during acute flares can worsen long-term outcomes, and ULT should be continued during flares 4

Febuxostat (80-120 mg) is more effective than fixed-dose allopurinol (300 mg) in achieving target serum urate levels <6 mg/dL in patients with gout, according to the American College of Rheumatology 5
Allopurinol should be started at a low dose (100 mg/day) and gradually increased by 100 mg increments every 2-4 weeks until target serum urate levels are achieved, as recommended by the American College of Rheumatology 5
The American College of Rheumatology recommends switching to febuxostat if allopurinol is not tolerated or if target serum urate levels cannot be achieved despite appropriate allopurinol dose titration 5, 6

Prophylaxis against acute gout flares should be provided when initiating either medication, typically with colchicine (0.5-1 mg/day) for the first 6 months, as recommended by the American College of Rheumatology 5, 7
Serum urate levels should be monitored regularly to ensure target levels (<6 mg/dL) are maintained, according to the American College of Rheumatology 5, 6
For patients with tophi, a lower target serum urate level (<5 mg/dL) is recommended by the American College of Rheumatology 5, 6